Background: There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children.
Methods: Charts from 291 youth with type 1 diabetes (T1D) who were treated with CSII therapy for at least 1 year were reviewed. Data analysis included hemoglobin A(1c)(HbA(1c)) values, body mass index (BMI) values, and the occurrence of severe hypoglycemia (SH) or diabetic ketoacidosis (DKA) events.
Results: For the 291 patients, the mean age (+/-SD) for beginning CSII therapy was 13.3 +/- 3.7 years. The mean duration of CSII was 3.7 +/- 1.9 years (range 1-9 years). The baseline HbA(1c) value was 8.7 +/- 1.0%, compared to 8.2 +/- 0.9% after 1 year (P < 0.0001). The most recent value for all patients was 8.3 +/- 1.3% (P < 0.0001 compared to the baseline values for the same subjects). There was no advantage in glycemic control in the teen years as a result of initiating CSII in the pre-teen years compared to the teen years. SH events decreased from 9.06 events per 100 patient-years before CSII therapy to 7.96 events per 100 patient-years while on CSII therapy. The incidence of DKA increased from 1.39 events pre-CSII to 3.98 events per 100 patient-years while on CSII therapy. BMI z-scores showed a nonsignificant increase.
Conclusions: The long-term use of CSII in pediatric patients is beneficial in lowering mean HbA(1c) levels and the number of SH events. However, there was an increase in the number of DKA episodes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/dia.2007.0214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.
JMIR Dermatol
November 2024
Rowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.
Article Synopsis
- Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are essential treatments for type 1 diabetes (T1D), but they may cause dermatologic complications like contact dermatitis and lipodystrophies, which negatively affect glycemic control and patient adherence.
- A systematic review analyzed 30 studies focusing on dermatologic issues related to CGM and CSII in pediatric patients, finding that contact dermatitis was the most common complication reported.
- The findings highlight the need for better manufacturer transparency and further research to address how these skin complications may impact long-term T1D management in young patients.
Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment.
J Diabetes Investig
November 2024
Department of Nutrition, The First People's Hospital of Nanning, Nanning, Guangxi, China.
Aim/introduction: To evaluate the therapeutic efficacy short-term continuous subcutaneous insulin infusion (CSII) intensive therapy combined with a low-carbohydrate diet (LCD) for diabetes remission in patients with newly diagnosed type 2 diabetes mellitus.
Materials And Methods: This study included patients newly diagnosed with type 2 diabetes mellitus, who were randomly divided into two groups: conventional (conventional CSII + traditional lifestyle guidance); and intensive (intensive CSII + LCD lifestyle guidance). CSII was used for blood glucose control, with continuous glucose monitoring (CGM) used to monitor blood glucose levels.
Diabetes Control and Clinical Outcomes among Children Attending a Regional Paediatric Diabetes Service in Australia.
Nutrients
November 2024
Bathurst Rural Clinical School (BRCS), School of Medicine, Western Sydney University, Bathurst, NSW 2795, Australia.
Australian children with diabetes commonly struggle to achieve optimal glycaemic control, with minimal improvement observed over the past decade. The scarcity of research in the rural and regional Australian context is concerning, given high incidence rates and prominent barriers to healthcare access in these areas. We conducted a retrospective audit of 60 children attending a regional Australian paediatric diabetes service between January 2020 and December 2023.
View Article and Find Full Text PDF[The use of TruCare III insulin pump in patients with type 1 diabetes mellitus].
Probl Endokrinol (Mosk)
November 2024
The development of devices for continuous subcutaneous insulin infusion (CSII or insulin pumps) dramatically improved medical care for patients with diabetes mellitus. Insulin pump production widens annually resulting in number of new models entering the market, that differs in price but are similar in technical features. The entering of such new models to the Russian market can cause practical issues both in patient and in health care provider, so their estimation is of great importance.
View Article and Find Full Text PDFEffect of Interrupting Prolonged Sitting with Frequent Activity Breaks on Postprandial Glycemia and Insulin Sensitivity in Adults with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy: A Randomized Crossover Pilot Trial.
Diabetes Technol Ther
November 2024
Physical Activity Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
This study examined acute effects of interrupting prolonged sitting with short activity breaks on postprandial glucose/insulin responses and estimations of insulin sensitivity in adults with type 1 diabetes (T1D). In a randomized crossover trial, eight adults (age = 46 ± 14 years [mean ± SD], body mass index [BMI] = 27.2 ± 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!